A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

NCT06786312 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

34

Enrollment

OTHER_GOV

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Apatinib
DRUG: Adebrelimab
DRUG: Etoposide Injection
DRUG: Carboplatin Injection

Sponsor

Fujian Cancer Hospital